reverse transcriptase inhibitor


Also found in: Dictionary, Thesaurus, Legal, Acronyms, Encyclopedia, Wikipedia.
Related to reverse transcriptase inhibitor: NNRTI, NRTI

inhibitor

 [in-hib´ĭ-tor]
1. any substance that interferes with a chemical reaction, growth, or other biologic activity.
2. a chemical substance that inhibits or checks the action of a tissue organizer or the growth of microorganisms.
3. an effector that reduces the catalytic activity of an enzyme.
ACE i's (angiotensin-converting enzyme i's) see angiotensin-converting enzyme inhibitors.
angiogenesis inhibitor a group of drugs that prevent growth of new blood vessels into a solid tumor.
aromatase i's a class of drugs that inhibit aromatase activity and thus block production of estrogens; used to treat breast cancer and endometriosis.
C1 inhibitor (C1 INH) a member of the serpin group, an inhibitor of C1, the initial component activated in the classical complement pathway. Deficiency of or defect in the protein causes hereditary angioedema.
carbonic anhydrase inhibitor an agent that inhibits the enzyme carbonic anhydrase; used in treatment of glaucoma and sometimes for epilepsy, familial periodic paralysis, acute mountain sickness, and kidney stones of uric acid.
cholinesterase inhibitor anticholinesterase.
COX-2 i's (cyclooxygenase-2 i's) a group of nonsteroidal antiinflammatory drugs that act by inhibiting cyclooxygenase-2 activity; they have fewer gastrointestinal side effects than other NSAIDs. Two members of the group are celecoxib and rofecoxib.
gastric acid pump inhibitor an agent that inhibits gastric acid secretion by blocking the action of H+,K+-ATPase at the secretory surface of gastric parietal cells; called also proton pump i.
HIV protease inhibitor any of a group of antiretroviral drugs active against the human immunodeficiency virus; they prevent protease-mediated cleavage of viral polyproteins, causing production of immature viral particles that are noninfective. Examples include indinavir sulfate, nelfinavir mesylate, ritonavir, and saquinavir.
HMG-CoA reductase i's a group of drugs that competitively inhibit the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis, and are used to lower plasma lipoprotein levels in the treatment of hyperlipoproteinemia. Called also statins.
membrane inhibitor of reactive lysis (MIRL) protectin.
monoamine oxidase inhibitor any of a group of drugs that inhibit the action of monoamine oxidase, the enzyme that breaks down norepinephrine and serotonin, prescribed for their antidepressant action; the most widely used ones are isocarboxazid, phenelzine, and tranylcypromine. They are also used in the prevention of migraine.
α2-plasmin inhibitor α2-antiplasmin.
plasminogen activator inhibitor (PAI) any of several regulators of the fibrinolytic system that act by binding to and inhibiting free plasminogen activator. Their concentration in plasma is normally low, but is altered in some disturbances of bodily hemostasis. PAI-1 is an important fast-reacting inhibitor of t-plasminogen activator and u-plasminogen activator. Its synthesis, activity, and release are highly regulated; elevated levels of it have been described in a number of disease states. PAI-2 is a normally minor inhibitor that greatly increases in concentration during pregnancy and in certain disorders. PAI-3 is protein C inhibitor.
platelet inhibitor any of a group of agents that inhibit the clotting activity of platelets; the most common ones are aspirin and dipyridamole. See also antiplatelet therapy.
protease inhibitor
1. a substance that blocks activity of endopeptidase (protease), such as in a virus.
protein C inhibitor the primary inhibitor of activated anticoagulant protein C; it is a glycoprotein of the serpin family of proteinase inhibitors and also inhibits several other proteins involved in coagulation (thrombin, kallikrein, and coagulation factors X and XI) and urokinase. Called also plasminogen activator inhibitor 3.
proton pump inhibitor gastric acid pump i.
reverse transcriptase inhibitor a substance that blocks activity of the reverse transcriptase of a retrovirus and is used as an antiretroviral agent. Some are nucleosides or nucleoside analogues, and those that are not are therefore often called non-nucleoside reverse transcriptase inhibitors.
selective serotonin reuptake inhibitor (SSRI) any of a group of drugs that inhibit the inactivation of serotonin by blocking its absorption in the central nervous system; used as antidepressants and in the treatment of obsessive-compulsive disorder and panic disorder.
serine protease inhibitor (serine proteinase inhibitor) serpin.
topoisomerase i's a class of antineoplastic agents that interfere with the arrangement of DNA in cells.

reverse transcriptase inhibitor

n. Abbr. RTI
Any of various antiviral compounds that interfere with the activity of the enzyme reverse transcriptase, which is found especially in retroviruses such as HIV. These compounds are divided into two classes: those that are nucleoside analogs (nucleoside reverse transcriptase inhibitors) and those that are not nucleoside analogs (non-nucleoside reverse transcriptase inhibitors).

reverse transcriptase inhibitor

a compound that inhibits the enzyme used by retroviruses to synthesize complementary DNA from viral RNA inside host cells.

reverse transcriptase inhibitor

Abbreviation: RTI
Any of a class of antiretroviral agents that competitively inhibit the reverse transcriptase enzyme of HIV and other viruses.
See: antiretroviral
See also: inhibitor
References in periodicals archive ?
For the initial part of the study, participants must have 100 to 300 CD4+ T cells per cubic millimeter (mm3) of blood, no serious signs or symptoms related to their HIV infection, no history of serious side effects to ddI or AZT and no previous treatment with non-nucleoside reverse transcriptase inhibitors.
Two-hundred eighty-three patients have received combination therapy with Emtriva and Viread with either a non-nucleoside reverse transcriptase inhibitor or protease inhibitor for 24 to 48 weeks in ongoing clinical studies.
In particular, the recent use of the nucleos(t)ide reverse transcriptase inhibitors abacavir and didanosine has been associated with myocardial infarction in the large DAD study cohort [1].
They recorded the incidence of myocardial infarction during the follow-up period and looked at the associations between myocardial infarction and exposure to protease inhibitors or non-nucleoside reverse transcriptase inhibitors.
The survey, which looked at specimens from 3,130 newly diagnosed, drug-naive individuals, found that 4% of infections had mutations conferring resistance to nucleoside reverse transcriptase inhibitors, 7% to nonnucleoside reverse transcriptase inhibitors, and 2% to protease inhibitors.
nucleoside analogue reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), RNA polymerase inhibitors, integrase inhibitors.
Nucleoside analog reverse transcriptase inhibitors (NRTIs), the first antiretroviral agents to be introduced to the market back in 1987, remain a mainstay of anti-HIV therapy.
But everything changed in the mid 1990s with the advent of two new classes of anti-HIV drugs--first in December 1995 with protease inhibitors, then in June 1996 with nonnucleoside reverse transcriptase inhibitors.
These drugs are other nucleoside reverse transcriptase inhibitors such as lamivudine, and nonnucleoside reverse transcriptase inhibitors such as nevirapine, and protease inhibitors such as indinavir and ritonavir.
The development of protease inhibitor drugs last year - and the discovery that their potency was enhanced when combined with an earlier class of drugs called reverse transcriptase inhibitors - meant that for the first time since the epidemic exploded in the early 1980s, patients can dare to hope.
A single dose of tenofovir and emtricitabine at delivery reduced resistance to nonnucleoside reverse transcriptase inhibitors at 6 weeks after delivery by half.
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild type and drug-resistant HIV variants.

Full browser ?